/PHAT
PHAT Stock - Phathom Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$17.53+7.68%
+$1.25 (+7.68%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+27.8%upside
Target: $22.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PHAT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$17.35 – $17.71
TARGET (TP)$22.40
STOP LOSS$16.13
RISK/REWARD1:3.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.43
52W High$17.70
52W Low$2.21
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $55.25M | $682,000 | N/A | N/A | N/A |
| Gross Profit | $47.28M | $515,000 | $-620,000 | $-521,000 | $-300,000 |
| Gross Margin | 85.6% | 75.5% | N/A | N/A | N/A |
| Operating Income | $-277,467,000 | $-167,312,000 | $-172,440,000 | $-135,080,000 | $-125,665,000 |
| Net Income | $-334,326,000 | $-201,592,000 | $-197,723,000 | $-143,883,000 | $-129,068,000 |
| Net Margin | -605.1% | -29558.9% | N/A | N/A | N/A |
| EPS | $-5.29 | $-3.93 | $-5.70 | $-4.00 | $-4.01 |
Company Overview
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
1
13%
Buy / Outperform
6
75%
Hold / Neutral
1
13%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish1 Neutral/Bearish
Price Targets
$23
Average Target
↑ 29.8% Upside
Now
$16
Low
$23
Average
$28
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | Raymond James | Initiation | Strong Buy | $28 |
| December 9th 2025 | Barclays | Initiation | Equal Weight | $16 |
| February 14th 2025 | Cantor Fitzgerald | Initiation | Overweight | $23 |
| May 3rd 2024 | Stifel | Initiation | Buy | $24 |
| January 5th 2024 | Needham | Reiterated | Buy | $26← $23 |
| August 9th 2023 | H.C. Wainwright | Initiation | Buy | $28 |
| May 11th 2023 | Evercore ISI | Upgrade | Outperform | - |
| March 13th 2023 | Craig Hallum | Initiation | Buy | $21 |
| October 21st 2022 | Jefferies | Initiation | Buy | $16 |
| May 6th 2022 | Evercore ISI | Downgrade | In-line | - |
Earnings History & Surprises
PHATBeat Rate
56%
Last 18 quarters
Avg Surprise
+6.5%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$-0.15
Q4 2025
EPS Surprise History
Q1 24
+13.0%
$-0.80vs$-0.92
Q2 24
+0.7%
$-1.42vs$-1.43
Q3 24
-4.2%
$-1.25vs$-1.20
Q4 24
+15.9%
$-1.32vs$-1.57
Q1 25
+38.8%
$-0.79vs$-1.29
Q2 25
-0.9%
$-1.07vs$-1.06
Q3 25
-3.9%
$-0.79vs$-0.76
Q4 25
+50.0%
$-0.15vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.10 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.30 | $-0.15 | +50.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.76 | $-0.79 | -3.9% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-1.06 | $-1.07 | -0.9% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-1.29 | $-0.79 | +38.8% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.57 | $-1.32 | +15.9% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.20 | $-1.25 | -4.2% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-1.43 | $-1.42 | +0.7% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.92 | $-0.80 | +13.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.95 | $-0.76 | +20.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.95 | $-0.84 | +11.6% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-1.34 | $-0.89 | +33.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-1.50 | $-1.33 | +11.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-1.32 | $-1.32 | 0.0% | = MET |
Q3 2022 | Aug 2, 2022 | $-1.03 | $-1.33 | -29.1% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.97 | $-1.07 | -10.3% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-0.86 | $-0.95 | -10.5% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.78 | $-0.98 | -25.6% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-1.07 | $-1.00 | +6.5% | ✓ BEAT |
Latest News
Phathom Pharmaceuticals Doses First Patient In Phase 2 pHalcon-EoE-201 Clinical Study Evaluating VOQUEZNA Tablets To Treat Eosinophilic Esophagitis
📈 PositiveBenzinga•Nov 4, 2025, 01:03 PM
PHAT stock has given up its prior gain. Phathom Pharmaceuticals shares were trading higher after HC Wainwright raised its price target from $20 to $26 on the stock.
➖ NeutralBenzinga•Oct 31, 2025, 04:22 PM
Phathom Pharmaceuticals shares are trading higher after HC Wainwright raised its price target from $20 to $26 on the stock.
📈 PositiveBenzinga•Oct 31, 2025, 01:30 PM
HC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $26
📈 PositiveBenzinga•Oct 31, 2025, 10:50 AM
Phathom Pharmaceuticals Raises FY2025 Sales Guidance from $165.000M-$175.000M to $170.000M-$175.000M vs $169.904M Est
📈 PositiveBenzinga•Oct 30, 2025, 11:24 AM
Phathom Pharmaceuticals Q3 Adj. EPS $(0.15), Sales $49.504M Beat $46.993M Estimate
📈 PositiveBenzinga•Oct 30, 2025, 11:21 AM
Reported Saturday, Phathom Pharmaceuticals Publishes Phase 3 pHalcon-NERD-301 Data Showing VOQUEZNA Rapidly Improves Nocturnal GERD Symptoms Through 24 Weeks
📈 PositiveBenzinga•Oct 27, 2025, 06:57 AM
Phathom Pharmaceuticals To Highlight Gastrointestinal Treatments Through Multiple Engagements Including A Product Theater Presentation On Voquezna Tablets For Gerd At American College Of Gastroenterology 2025 Annual Scientific Meeting In Phoenix, Arizona.
➖ NeutralBenzinga•Oct 23, 2025, 12:14 PM
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial And Business Officer
➖ NeutralBenzinga•Oct 6, 2025, 12:11 PM
Phathom Pharmaceuticals Clarifies That Scheduled 13D Filing By Frazier Life Sciences Includes Administration Changes To Reporting Approach But Does Not Represent Reduction In Ownership Position Of Any Frazier Fund Or Person In Phantom
📈 PositiveBenzinga•Aug 20, 2025, 12:07 PM
Phathom surges 125% after FDA grants petition on Voquezna exclusivity
📈 PositiveSeeking Alpha•Jun 6, 2025, 04:27 PM
Phathom Pharmaceuticals surges 50% following large insider purchase
📈 PositiveSeeking Alpha•May 9, 2025, 04:23 PM
Frequently Asked Questions about PHAT
What is PHAT's current stock price?
Phathom Pharmaceuticals, Inc. (PHAT) is currently trading at $17.53 per share. The stock has moved +7.68% today.
What is the analyst price target for PHAT?
The average analyst price target for PHAT is $22.40, based on 1 analyst.
What sector is Phathom Pharmaceuticals, Inc. in?
Phathom Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PHAT's market cap?
Phathom Pharmaceuticals, Inc. has a market capitalization of $1.25 billion, making it a small-cap company.
Does PHAT pay dividends?
No, Phathom Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
BCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to PHAT for comparison